More Isn't Better: How Prescription Farms Are Getting Hormone Therapy Wrong

The business model of the subscription hormone clinic is straightforward: a monthly fee, a standard kit, an algorithm that approves most applicants, and a refill that continues until the customer cancels. It is an efficient operation. It is not medicine. And for the women who receive treatment through it, the consequences of that distinction are not abstract.

The hormone therapy space has industrialised in the last decade. Venture-backed companies with healthcare branding have built nationwide platforms that connect women with prescriptions more quickly and cheaply than any traditional medical practice can. Some of them have done something genuinely useful — they have normalized the conversation about menopause and made it easier for women to seek help. But the model they have built around that normalization is not delivering care. It is delivering convenience.

The Problem with Standard Dosing

Hormone therapy requires individualization because hormone levels, metabolism, and symptom response vary enormously between women. Two women of the same age with the same presenting symptoms may have completely different estradiol levels, different progesterone needs, and different testosterone requirements. A dose that is appropriate for one may be inadequate for the other — or excessive.

Subscription platforms typically offer a limited range of standardized protocols. The assessment is based on a questionnaire, not a comprehensive hormone panel. The prescribing decision is made without knowing a patient's actual hormone levels. This is not medicine. It is customer acquisition with a prescription attached. The result is that many women receive treatment that is not calibrated to their actual biology — and never know the difference, because no one has measured what "calibrated" would look like for them specifically.

The Monitoring Gap

Even when initial dosing is reasonable, hormone therapy requires monitoring. Labs should be reviewed at three and six months to assess whether levels have reached the therapeutic range, whether the patient is responding, and whether any adjustments are needed. Without monitoring, the dose that was appropriate at month one may be wrong at month six — because absorption rates vary, because the patient's own production has changed, or because the treatment objective has been met and the dose needs to be reconsidered.

Subscription platforms typically do not include systematic monitoring. There may be a check-in questionnaire or an optional lab review for an additional fee. But there is no physician who owns the monitoring obligation, no one who will flag a lab result and reach out proactively, no clinical accountability for the patient's ongoing status. The subscription refills regardless.

What Proper Care Actually Looks Like

IHA's BHRT program starts with a complete hormone panel — estradiol, progesterone, FSH, testosterone, DHEA-S, and SHBG — before any prescribing decision is made. Dosing is individualized to those results and to the patient's symptom picture. Labs are reviewed at three and six months, with adjustments made by the physician overseeing care. If a patient's situation changes — a new health condition, a new medication, a shift in symptoms — that is a clinical event that affects the treatment, not just an administrative note.

This is what distinguishes physician-directed care from subscription delivery. A prescription farm will prescribe to almost anyone who applies and pays. A medical practice will prescribe to the patients for whom it is clinically appropriate, at doses that reflect actual biology, with monitoring that catches what needs catching. The distinction is not philosophical. It is the difference between treatment and its simulation.

If you are currently receiving hormone therapy through a subscription service and have never had your hormone levels tested before or during treatment, it may be worth asking for that data. What it shows — or the conversation you have when you ask for it — will tell you something important about the nature of the care you are receiving.

The Subscription Model's Structural Problem

Understanding why prescription farms operate the way they do requires understanding their business model. They are venture-capital-funded technology companies with a healthcare license — not medical practices that happen to use technology. Their unit economics depend on customer acquisition, monthly subscription retention, and minimizing the cost per interaction. Every physician consultation, every lab review, every clinical adjustment costs them money. Every month a subscription renews without requiring clinical attention is pure margin.

This structure creates incentives that run directly counter to good clinical practice. Ordering labs for every patient is expensive and adds friction that reduces sign-up conversion. Requiring clinical follow-up means physician time that needs to be paid for. Declining patients who are not appropriate candidates means lost revenue. Reducing doses when patients experience side effects means patient dissatisfaction and subscription cancellation. None of these commercially inconvenient outcomes are in the financial interest of a subscription model — which means that the model systemically discourages them, often through the way protocols are designed rather than through any individual bad actor.

The result is that the patients who sign up for these services are often receiving treatment that reflects the company's cost structure more than their clinical needs. Standard doses because individualization is expensive. No monitoring because monitoring costs physician time. Continued prescriptions regardless of response because interrupting the subscription is a customer service failure. This is not what medicine looks like. It is what a product looks like.

The Safety Implications of Unsupervised Dosing

Hormone therapy that is not supervised produces safety risks that are not theoretical. Estrogen therapy without adequate progesterone in women who retain a uterus creates endometrial hyperplasia risk — the uterine lining becomes overstimulated and can progress to endometrial cancer if the imbalance is not corrected. Subscription platforms that provide estrogen without assessing whether the patient is on appropriate progesterone, or without monitoring to ensure the progesterone is being absorbed and used effectively, are exposing patients to a real clinical risk that a physician monitoring labs would catch in a routine blood draw.

Testosterone therapy for women, at the doses used in clinical practice, has a narrow therapeutic range. Levels above the physiological ceiling for women produce masculinising effects — acne, hair changes, voice deepening — that, while reversible, are distressing and avoidable with appropriate monitoring. Subscription platforms that provide testosterone without pre-treatment baseline labs and without routine monitoring cannot identify when levels are exceeding the appropriate range — because they have not measured the starting point and are not measuring the current level.

These are not edge cases. They are predictable consequences of a model that does not include the clinical monitoring that the medication category requires. IHA's approach — BHRT delivered under physician oversight with baseline and follow-up labs — exists specifically because the alternative exposes patients to risks that proper clinical management prevents. The monthly cost difference between a well-supervised program and a subscription platform is not a price premium for the same product. It is the cost of actual medicine versus its simulation.

A Practical Test: How to Evaluate Any Clinic Before You Commit

The structural problems with commercial hormone and weight loss subscription platforms are not hidden — they are built into the business model. But the distinction between a real medical practice and a commercial service is not always obvious from a website, and women who have been harmed by unsupervised prescribing typically describe the intake process as appearing legitimate. A specific evaluation checklist — questions that have different answers at a real clinical practice versus a subscription operation — provides a reliable filter before you commit time, money, or your health to any program.

The first question is foundational: can you tell me the name of the physician who will prescribe for me, and is that physician licensed in my state? A real medical practice can answer this immediately with a specific name. A licensed physician's credentials are publicly verifiable through your state's medical board website, typically within two minutes of searching. Subscription platforms frequently use what is called a "Medical Director" whose name may appear in documentation but who does not actually review individual patient cases. If the answer to this question is a general description of a clinical team rather than a specific physician name and license number, that is a significant red flag. In a legitimate practice, the prescribing physician is a named individual who carries legal responsibility for that prescription decision.

The second question is about laboratory protocol: what labs do you order, at what frequency, and who reviews them? The minimum acceptable answer for a BHRT program includes a comprehensive hormone panel before initiation, a follow-up panel at eight to twelve weeks to verify therapeutic levels, and ongoing monitoring at defined intervals thereafter. For a GLP-1 program, baseline metabolic labs including fasting glucose, HbA1c, kidney function, and lipids are appropriate, with follow-up monitoring for women on longer-term therapy. A subscription service that does not require baseline labs, or that presents lab-optional intake as a convenience feature, is not practicing medicine — it is dispensing medication without the clinical information required to do so safely. The endometrial hyperplasia risk from unopposed estrogen is a direct clinical consequence of failing to prescribe progesterone when it is indicated, which cannot be determined without knowing a patient's hormonal status.

The third question is about pharmacy: what pharmacy fills my prescription, and is it a 503B outsourcing facility? The distinction between 503A and 503B compounding facilities matters for quality assurance, as covered in detail in the post on bioidentical versus synthetic hormones. A practice that sources from a registered 503B facility can confirm that facility's name and FDA registration status. A practice that sources from a network of 503A pharmacies — or that does not know the answer — cannot provide the same quality assurance.

The fourth question addresses clinical access: what happens if I have a concern between scheduled appointments? A real clinical practice has a defined pathway for clinical questions — typically a patient portal message reviewed by a clinical staff member, with physician review for clinical concerns that cannot be resolved by protocol. A subscription service has customer service. The difference matters when you experience a side effect, need a dose adjustment, or have a clinical question that requires a physician to assess. A practice that cannot describe its between-appointment clinical communication process in specific terms has told you something important about how your care will actually be managed.

The fifth question tests the integrity of the clinical process: what is your policy if I am not an appropriate candidate for this treatment? A real medical practice declines candidates when clinical assessment identifies contraindications — personal history of hormone-sensitive cancer, untreated cardiovascular disease, specific thyroid conditions, or metabolic factors that make a particular protocol inappropriate. The honest answer is that a meaningful percentage of initial inquiries do not result in a prescription, and that the assessment is designed to identify that. The post on when real medicine says no covers the clinical value of that process in detail. A subscription service that implies it rarely or never declines patients — or that frames declining as a failure rather than a clinical decision — has revealed that its intake process is not actually functioning as clinical gatekeeping.

A practice that can answer all five of these questions specifically, accurately, and without hesitation is demonstrating that it operates as a medical practice rather than a commercial platform. Applying this checklist before committing to any clinic takes under thirty minutes and provides a reliable basis for comparison. For an understanding of what a clinic that passes this evaluation looks like in full detail, the next post in this series applies the same framework directly to IHA's own practice. You can also contact IHA directly and ask these questions yourself — the answers should be immediate and specific.

A note on how to use this checklist practically: the goal is not to conduct a hostile interrogation of every hormone clinic you encounter. The goal is to distinguish practices that can answer these questions — because they operate as medical practices and have the clinical infrastructure to do so — from those that cannot. A practice with a real clinical foundation will not be threatened by these questions. The physician's license number is public information. The lab protocol is a standard component of any clinical intake documentation. The pharmacy category is a factual answer. The between-appointment access pathway is a design choice that a real practice has made and can describe. When you ask these questions and receive specific, verifiable answers, you have useful information about the practice's clinical structure. When you ask and receive vague reassurances, marketing language, or deflection, you also have useful information — just not the kind that supports moving forward. The five questions above take under fifteen minutes to ask and answer across a phone call or a patient portal message. That fifteen minutes is worth investing before committing to any clinical program that will manage your health over months or years.

The Clinical Questions That Separate Medical Practice from Subscription Operations

The most useful framework for evaluating any hormone or weight loss clinic is not the website copy or the patient testimonials — it is the clinical questions they are willing to answer. A few worth asking directly: who is the specific physician managing my care, and what are their credentials in hormonal medicine? What is the monitoring protocol after my initial prescription — when are follow-up labs ordered, and who reviews them? If I experience a side effect between appointments, what is the clinical response pathway? If my clinical picture suggests I am not a good candidate for the treatment I am requesting, how does your practice handle that?

Clinics that are practicing medicine answer these questions specifically and confidently. Clinics that are operating subscription services often cannot answer them at all, because the service does not include the components the questions are asking about. A full framework for evaluating any hormone or GLP-1 clinic gives you the complete set of questions worth asking before committing to care. IHA answers all of them — not because the practice has a good marketing response but because the service is structured around the clinical components those questions are evaluating.

The Institutional Markers That Matter

Beyond the clinical questions worth asking, there are institutional markers that distinguish medical practices from commercial operations in the GLP-1 and hormone therapy space. A licensed pharmacy dispensing the medication — not a loosely regulated supplier. A clear state medical license for the prescribing physician. Transparent communication about who owns and operates the practice. Terms of service that address what happens to your clinical records and personal health information. A complaint pathway that leads to a licensed medical board rather than only to a commercial dispute resolution process.

These markers are verifiable before you enroll. The New Hampshire Board of Medicine maintains a public license verification database. A compounding pharmacy's 503A status is publicly listed. A physician's malpractice history is part of the public record in most states. The few minutes spent on these verifications before committing to a treatment relationship are a reasonable due diligence step for a health decision that you may be in for months or years. IHA is verifiable on every one of these dimensions. Starting with a consultation gives you a direct opportunity to ask these questions and receive direct answers.